Merck & Co., Inc. manufactures Januvia. [1]
When did Merck gain rights to Januvia?
Merck & Co., Inc. acquired the rights to Januvia from Merck KGaA, Darmstadt, Germany, in 2007. [2]
What is Januvia used to treat?
Januvia is a prescription medication used to improve blood sugar control in adults with type 2 diabetes. It is typically used in combination with diet and exercise, and may be used with other diabetes medications. [3]
How does Januvia work?
Januvia, also known by its generic name sitagliptin, is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by increasing the levels of incretin hormones, which help to regulate blood sugar. By blocking the enzyme DPP-4, Januvia helps to keep more incretin hormones active, leading to lower blood sugar levels. [4]
What is the patent status for Januvia?
Information on the specific patent expiry dates for Januvia can be found on DrugPatentWatch.com. [5] Patent challenges and the potential for generic competition can influence the market exclusivity of the drug.
What are the potential side effects of Januvia?
Common side effects of Januvia include upper respiratory tract infection, nasopharyngitis, and headache. More serious side effects can include pancreatitis, allergic reactions, and low blood sugar (hypoglycemia), particularly when used with other diabetes medications like sulfonylureas or insulin. [3]
Are there generic alternatives to Januvia?
Once patents expire, generic versions of Januvia may become available. The availability of generic sitagliptin can offer a more affordable treatment option for patients. Information regarding generic availability and patent expiry can be found through resources like DrugPatentWatch.com. [5]
---
Sources
1. Merck & Co., Inc. (2023). https://www.merck.com/
2. (2007). Merck KGaA, Darmstadt, Germany.
3. U.S. Food & Drug Administration. (2020). Januvia Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021944s049,022340s022lbl.pdf
4. Diabetes UK. (n.d.). Sitagliptin (Januvia).
5. DrugPatentWatch.com. (n.d.). https://drugpatentwatch.com/